Sanofi Won’t Discount Toujeo More Than Lantus Blockbuster
This article is for subscribers only.
Sanofi is caught between a rock and a hard place when it comes to promoting its new insulin.
The French drugmaker believes the new product, Toujeo, is better than its aging diabetes blockbuster Lantus for stabilizing blood-sugar levels but it can’t say so as a result of a recent U.S. regulatory ruling. And now it says it won’t offer a steeper discount to sway pharmacy benefit managers.